Microplastics in the marine environment of St. Mary's Island: implications for human health and conservation.

Microplastics have now been identified as a class of emerging pollutants and is considered as a threat to aquatic organisms. This baseline paper investigated the distribution, composition, and potential ecological risks of microplastic (MP) pollution on St. Mary's Island, revealing an average abundance of 0.218 particles/L in water samples. Blue fibres and white foams were the primary MPs identified, and fishing activities and packaging were the main sources of pollution. Six types of polymers were identified: low-density polyethylene (LDPE), polystyrene (PS), polyamide (PA), polypropylene (PP), polyethylene (PE), and high-density polyethylene (HDPE). The Polymer Hazard Index (PHI) and Potential Ecological Risk Index (PERI) indicated a medium environmental risk for the island. Additionally, it was discovered that MPs' surfaces contained dangerous substances that could endanger aquatic life. The research emphasizes the significance of implementing measures such as responsible disposal, management, elimination, regulatory policies, and local administration techniques to mitigate the impact of MP pollution on the island's shores and marine biota. This research provides a baseline for monitoring MP contamination and underscores the need for continuous investigation to assess their impacts on marine life.

A baseline study of microplastic pollution in a Southern Indian Estuary.

Knowledge on the processes controlling the vertical distribution of microplastics (MPs) in estuaries is less. This research was carried out to determine the MP distribution in the surface, middle, and bottom layers of the Udyavara River Estuary in southwest India. The mean (± standard deviation) concentrations were 320.83 (± 98.30), 514.55 (± 352.16), and 755.03 (± 400.96) particles/m3, respectively. Fibres, films, and fragments dominated, and 57 % of the MPs had a size range of 0.3-1 mm, while 43 % had a size of 1-5 mm. The main polymers were high-density polyethylene and polyethylene terephthalate. A positive correlation (r = 0.421, p = 0.0205, n = 30) exists between the MPs and salinity, suggesting that the MPs are held by dense saline waters. The mean pollution load index value was 2.25 indicating severe pollution. Microplastic pollution is due to harbour, fishing, industrial activities, the effects of southwest monsoon rain, and tidal currents.

Hidden problems in geological heritage sites: The microplastic issue on Saint Mary's Island, India, Southeast Arabian Sea.

Microplastics (MPs) have become a dominant constituent of several oceanic islands. This study focuses on the occurrence and distribution of MPs present in the beach sediments of Saint Mary's Island (SMI), a geological heritage site located in the south-eastern part of the Arabian Sea. The average (standard deviation) abundance of MPs on this island was 97.18 (80.49) particles/kg. Attenuated total reflectance-Fourier transform infrared (ATR-FTIR) spectroscopy revealed that MPs are composed of high-density polyethylene (HDPE), low-density polyethylene (LDPE), polyethylene (PE), polypropylene (PP), polystyrene (PS), and polyamide (PA). Scanning Electron Microscopy (SEM) and Energy-Dispersive X-ray Spectroscopy (EDS) highlighted the presence of Cr, As, Pb, and Cd (harmful pollutants) on MP surfaces. The MPs in the SMI are largely contributed by the nearby fishing harbour, touristic beaches and estuaries. The results of this study, act as a starting point for continuous environmental monitoring in this unique region of the world.

Prevalence of renal artery stenosis requiring revascularization in patients initially referred for coronary angiography.

To evaluate the prevalence of clinically significant renal artery stenosis (RAS) in patients referred for coronary angiography, we analyzed data on 2,439 consecutive patients. Patients underwent selective renal angiography in conjunction with coronary angiography if refractory hypertension (blood pressure > 140/90 on two drugs) or flash pulmonary edema was present. A total of 1,089 renal arteries of 534 patients were evaluated. Twelve percent (137/1,089) of the renal arteries in 19% (101/534) of patients had > 70% diameter stenosis in at least one vessel. Bilateral renal artery stenosis was present in 26% (26/101) of patients. One hundred and thirty-two of the 137 vessels underwent stent revascularization due to clinical renovascular hypertension. Acute clinical success (< 20% diameter stenosis without death or urgent surgery) was 98% (99/101). Due to high prevalence and effective available treatment, we recommend routine screening for RAS in all patients with refractory hypertension referred for coronary angiography.

Safety of therapeutic beta-blockade in patients with coexisting bronchospastic airway disease and coronary artery disease.

Atherosclerotic coronary artery disease and bronchospastic airway disease frequently coexist in older patients. There are substantial data suggesting reduced mortality with the use of beta-adrenergic blocking drugs in patients with symptomatic coronary artery disease, especially patients who have postmyocardial infarction and/or severe coronary artery disease associated with left ventricular dysfunction. Conversely, the use of beta-adrenergic blocking drugs (even selective beta(1)-adrenergic blocking drugs) has the potential of exacerbating bronchospasm. This prospective registry evaluates the safety of use of selective beta(1)-adrenergic blocking drugs in patients with symptomatic coronary artery disease and bronchospastic airway disease. A total of 835 consecutive patients with symptomatic coronary artery disease were prospectively evaluated for coexisting coronary and bronchospastic airway disease. Of these, 30 patients (mean age: 61 +/- 14 years) met the qualifying inclusion criteria. All these study patients except 1 (29/30 [96%]) reached therapeutic beta-blockade (resting heart rate <70 beats per minute). The 1 patient who discontinued use of beta-adrenergic blocking drugs as a result of lifestyle-limiting bronchospasm had no serious adverse outcome. No hospitalizations were required because of worsening bronchospasm. Ten percent of patients reported increased requirement of inhaled beta(2)-agonist use. The patients were followed for 15 +/- 9 months. One patient died of stroke at 22 weeks of follow-up. In conclusion, use of selective beta(1)-adrenergic blocking drugs at a therapeutic dose is safe (as long as careful clinical follow-up is available) and should be considered in all patients with coexisting symptomatic coronary artery disease and bronchospastic airway disease.